| 43.01 -1 (-2.27%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 52.49  |
1-year : | 57.9 |
| Resists | First : | 44.94 |
Second : | 49.58 |
| Pivot price | 45.81 |
|||
| Supports | First : | 37.43 |
Second : | 31.15 |
| MAs | MA(5) : | 43.75 |
MA(20) : | 45.36 |
| MA(100) : | 38.76  |
MA(250) : | 29.12 |
|
| MACD | MACD : | 0.5 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 16.7 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 49.58 | Low : | 15.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRNX ] has closed above bottom band by 5.7%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.67 - 44.91 | 44.91 - 45.11 |
| Low: | 42.11 - 42.46 | 42.46 - 42.74 |
| Close: | 42.5 - 43.01 | 43.01 - 43.43 |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Wed, 17 Apr 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $639,256.25 in Stock - MarketBeat
Sun, 14 Apr 2024
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Canada Shine On
Thu, 11 Apr 2024
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tue, 26 Mar 2024
Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) - Yahoo Finance
Fri, 22 Mar 2024
Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) - Yahoo Finance
Wed, 20 Mar 2024
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 6.474e+007 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 4,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2151e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 547.1 % |
| Return on Equity (ttm) | -28.2 % |
| Qtrly Rev. Growth | 4.01e+006 % |
| Gross Profit (p.s.) | -161.3 |
| Sales Per Share | -80.91 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -166 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.54 |
| Price to Cash Flow | 3.37 |
| Dividend | 0 |
| Forward Dividend | 4.91e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|